807342-01-4

Upstream product

• 263769-24-0 (+)-4β-(4-Chlorophenyl)-3α-(hydroxymethyl)-1-methylpiperidine 
• 263769-22-8 (+)-methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylate 

Downstream Products

• 807342-02-5 (+)-2-[[(3R,4S)-4-(4-chlorophenyl)-1-methylpiperidin-3-yl]methylsulfanyl]acetic acid methyl ester 
• 807342-10-5 (+)-benzoic acid 2-[[(3R,4S)-4-(4-chlorophenyl)-1-methylpiperidin-3-yl]methylsulfanyl]ethyl ester 
• 807342-16-1 (+)-2-[[(3R,4S)-4-(4-chlorophenyl)-1-methylpiperidin-3-yl]methylsulfanyl]-N-isopropylacetamide 
• 807342-24-1 (+)-(3R,4S)-[[4-(4-chlorophenyl)-1-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)methylsulfanyl]methyl]piperidine 
• 807342-18-3 (+)-2-[[(3R,4S)-4-(4-chlorophenyl)-1-methylpiperidin-3-yl]methanesulfinyl]acetamide 
• 807342-08-1 (+)-acetic acid 2-[[(3R,4S)-4-(4-chlorophenyl)-1-methylpiperidin-3-yl]methylsulfanyl]ethyl ester 
• 807342-13-8 (+)-2-[[(3R,4S)-4-(4-chlorophenyl)-1-methylpiperidin-3-yl]methylsulfanyl]-N-hydroxyacetamide 
• 807342-15-0 (+)-2-[[(3R,4S)-4-(4-chlorophenyl)-1-methylpiperidin-3-yl]methylsulfanyl]-N,N-dimethylacetamide 
• 807342-12-7 (+)-2-[[(3R,4S)-4-(4-chlorophenyl)-1-methylpiperidin-3-yl]methylsulfanyl]acetamide 
• 807342-27-4 (+)-2-[[(3R,4S)-4-(4-chlorophenyl)piperidin-3-yl]methylsulfanyl]acetamide 
• 807342-14-9 (+)-2-[[(3R,4S)-4-(4-chlorophenyl)-1-methylpiperidin-3-yl]methylsulfanyl]-N-methylacetamide 
• 807342-06-9 (+)-(3R,4S)-4-(4-chlorophenyl)-3-[(2-methoxyethylsulfanyl)methyl]-1-methylpiperidine 

Relevant academic research and scientific papers

Development of new brain imaging agents based upon nocaine-modafinil hybrid monoamine transporter inhibitors

11C-labeled (+)-trans-2-[[(3R,4S)-4-(4-chlorophenyl)-1-methylpiperidin-3-yl]methylsu lfanyl]ethanol ([11C]5) and (+)-trans-2-[[(3R,4S)-4-(4-chlorophenyl)-1-methylpiperidin-3-yl]methylsu lfanyl]-1-(piperidin-1-yl)ethanone ([11/s

DOPAMINE-, NOREPINEPHRINE- AND SEROTONIN- TRANSPORTER- SELECTIVE HETEROCYCLIC COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS

One aspect of the invention relates to piperidine compounds that are useful as inhibitors of monoamine transporters. The invention also relates to pharmaceutical compositions, comprising a piperidine compound of the invention. Another aspect of the presen

Piperidine-based nocaine/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: Efficient drug discovery by rational lead hybridization

Some piperidine-based nocaine/modafinil hybrid ligands have been designed, synthesized, and found to display an improved potency at all three monoamine transporters and particularly for DAT and/or NET. Some highly active and selective monoamine transporte